BioStock: Stayble approaches study results and other milestones

Stayble Therapeutics is facing an eventful 2023 with expected data reporting from the phase IIb study with STA363. Patient recruitment was completed in 2022 and the six-month follow-up is predicted to be completed in the spring. In addition, the partnering discussions and preparations for phase III are now intensified. This includes a pre-IND meeting with the FDA, according to CEO Andreas Gerward.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/01/stayble-approaches-study-results-and-other-milestones/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se